מתוך medicontext.co.il
NEW YORK (Reuters Health) – Pfizer Inc. said on Monday that the US Food and Drug Administration (FDA) has approved the company's oral antibiotic Zithromax (azithromycin) as both a single-dose and three-day regimen for the treatment of pediatric middle ear infections.
Previously, the drug was approved as a once-daily five-day regimen for the infections.
The company noted that the single-dose regimen is not only effective, but also helps with patient compliance.
Pfizer said it expects to introduce Zithromax as a single-dose regimen early next year.
During late-day trading on the New York Stock Exchange, shares of the New York City-based firm were up 1.44 at 40.88.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!